Article Text

Download PDFPDF
Major UK non-commercial sponsors’ efforts to reduce research waste: a mixed-methods study
  1. Till Bruckner1,2,
  2. Aminul Schuster3,
  3. Belén Chavarría4,
  4. Carolina Cruz5,
  5. Fabiola Karely Lizárraga Illán5,
  6. Ronak Borana6,
  7. Tungamirai Ishe Bvute7,
  8. Daniel Sánchez5
  1. 1UiT The Arctic University, Tromso, Norway
  2. 2TranspariMED, Bristol, UK
  3. 3University of Westminster, London, UK
  4. 4National Autonomous University of Nicaragua-Leon, Leon, Nicaragua
  5. 5Universidad de Guadalajara, Guadalajara, Mexico
  6. 6XLRI, Jamshedpur, Jharkhand, India
  7. 7Independent Researcher, Dublin, Ireland
  1. Correspondence to Dr Till Bruckner, UiT The Arctic University of Norway, Tromso, Troms, Norway; tillbruckner{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Worldwide, a significant proportion of clinical trials end up as costly research waste because their results are never made public.1–3 The resulting gaps in the medical evidence base harm patients and undermine public health.4 The Declaration of Helsinki and the WHO both call for all clinical trial results to be made public.5 6

In the wake of a 2018 UK parliamentary enquiry, non-commercial clinical trial sponsors in the UK substantially improved outcome reporting for drug trials (Clinical Trials of Investigative Medicinal Products, CTIMPs) by uploading the summary results of many CTIMPs onto the European Union Clinical Trials Register (EUCTR) which exclusively lists drug trials. However, these efforts typically did not extend to other types of trials, which are listed on other trial registries.

This study assesses the current publication status of 145 clinical trials that are not CTIMPs that were sponsored by ten major UK non-commercial sponsors and were completed or terminated in 2017, allowing a 5-year follow-up period for publication.

The lead researcher (TB) identified the 10 most prolific non-commercial sponsors of clinical trials in the UK by accessing the EU Trials Tracker on 27 October 2022, employing the …

View Full Text


  • X @TranspariMED, @aminul_schuster, @BelnChavarria03

  • Contributors TB conceived and designed the study, wrote the protocol and drafted the manuscript. AS, BC, CC, FKLI, RB, TIB and DS extracted and analysed the data, and critically reviewed the manuscript prior to submission. All authors approved the final manuscript and agreed to be held accountable for its contents.

  • Funding This study was funded by HealthSense UK (none).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.